GLP-1 Drugs: The Muscle You Don't Defend Is the Muscle You Lose

You have probably seen the face by now. Someone you have not run into for a few months turns up 13kg (thirty pounds) lighter, and instead of looking like a fitter version of themselves, they look like a deflated one. The cheeks have gone hollow. The jawline has softened rather than sharpened. There is a tiredness to it that reads as older, not leaner. The internet calls this "Ozempic face," which is a tidy name for something that is not really about the face at all.

What you are actually looking at is the visible edge of a quieter problem. When weight comes off fast, it does not come off as pure fat. It comes off as a mix, and part of that mix is muscle and the connective scaffolding underneath the skin. The face shows it first because it has so little to spare. The rest of the body is doing the same thing where you cannot see it.

I am bringing this up now because the drugs are about to get a lot stronger.

What retatrutide actually does

Retatrutide is an experimental obesity drug from Eli Lilly, and it is the one worth understanding before it arrives in earnest. The current generation, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), works mostly by turning down appetite. Retatrutide does that too, but it pulls three levers instead of one. It activates the GLP-1 receptor to reduce appetite, the GIP receptor which influences how the body handles fuel, and the glucagon receptor, which appears to raise energy expenditure. Some people have started calling it "GLP-3" as shorthand. That is a marketing phrase rather than a scientific category, but it captures the idea well enough: this is a bigger lever.

The trial numbers are why everyone is paying attention. In phase 2 work, participants on the highest dose lost close to a third of their body weight over roughly eighty weeks, which puts it in territory previously reserved for bariatric surgery. That is genuinely remarkable, and I do not want to wave it away. For a lot of people, a drug like this will be the difference between a manageable life and a difficult one.

But power cuts both ways, and this is where I get opinionated.

The muscle question nobody wants to hear

There is a comforting story going around that retatrutide is "muscle sparing," meaning it somehow lets you shed fat while protecting lean tissue. I would be careful with that. The published human data does not support it yet. At higher doses, somewhere around 38 percent of the weight lost was lean mass, which is roughly in line with what the older GLP-1 drugs already do. The reassuring claim is running ahead of the evidence.

And preventing it is not mysterious. It is protein and it is resistance training. If you go on one of these drugs, eat far less than before, and do nothing to defend your muscle, you will lose muscle. That is not a risk, it is close to a certainty. The drug suppresses your appetite, which means the protein you used to eat by default now has to be a deliberate decision. The drug does not make you lift. You make you lift. A person who drops thirty pounds while keeping their squat is in a completely different place, biologically, than a person who drops thirty pounds and can no longer get off the floor without their hands. The scale cannot tell those two apart. Your future self can.

The heart rate signal

The most careful breakdown of retatrutide I have read comes from Dr. Nick Norwitz, whose work I follow closely and pay for, and whose general posture toward hype I trust. He ran the drug on himself for a short stretch and tracked more than a hundred biomarkers, which is exactly the kind of patient, slightly obsessive self-experiment that earns attention.

His most striking observation was cardiac. His resting heart rate, which sat in the low 40s as a fit person, climbed into the 60s and 70s on the drug. His heart rate variability dropped and his body temperature rose. Read one way, that is the glucagon mechanism doing its job: more energy expenditure, a higher metabolic idle. Read another way, a resting heart rate that jumps more than twenty beats and a falling HRV are the kind of signals you would not normally shrug off. For context, the formal trials reported smaller average increases of roughly five to seven beats per minute at the high doses, so an individual response can run well past the group mean.

The honest answer is that we do not yet know what those changes mean over years. A higher resting heart rate is generally associated with worse long-term outcomes across a population, but we cannot assume a drug-induced rise carries the same risk as a lifestyle-driven one. Norwitz's own framing is the right one: the effect is real, the long-term meaning is unclear, and "unclear" is not the same as "fine." He also noted his sleep got worse and an inflammation marker ticked up, which is the sort of downstream cost that does not show on a scale either.

What I would actually track

None of this is an argument against the drugs. It is an argument against treating them as a substitute for the work. If anything, a more powerful drug raises the stakes on the fundamentals, because it removes the natural brake that hunger used to provide.

If you are on a GLP-1, or planning to be, these are the things worth watching, and none of them is your weight:

• Are you hitting a real protein target every day, not just on the days you feel like eating?
• Are you lifting something heavy at least twice a week, with the intent to keep strength rather than just to move?
• Is your resting heart rate drifting up, and by how much?
• Is your sleep holding, or quietly eroding?
• Can you still do the physical things you could do three months ago?

That last one is the test that matters. Getting smaller is easy to measure and easy to celebrate. Staying capable is harder to see and far more worth protecting.

The drug is a lever. A bigger lever moves more weight, and it also breaks more things if you have not built the structure to handle it. Build the capacity. Do not gamble it on the assumption that the strongest version of the drug will somehow also be the gentlest.

---

A note on what this is and is not. I am not a doctor, and nothing here is medical advice. Retatrutide is experimental and not approved for general use. GLP-1 medications are powerful prescription drugs with real risks and real benefits, and decisions about them belong between you and a qualified physician who knows your history. If you are considering one, or are already on one, talk to your doctor before changing anything, including how you train and eat.